Volatility is again picking up, and it’s a good idea to focus more on safety. There’s no better way to do so than to buy ...

The market’s fear gauge tells the story clearly. The VIX hit 21.15 as of March 4, 2026, up 29.4% in a single month. Consumer ...

Johnson & Johnson (NYSE:JNJ) is included among the 13 Best Defensive Dividend Stocks for 2025. On March 3, BofA analyst Jason Gerberry raised the firm’s price recommendation on Johnson & Johnson (NYSE ...

On Thursday, the U.S. Food and Drug Administration approved Johnson & Johnson‘s JNJ Tecvayli in combination with Darzalex ...

Food ‌and Drug ‌Administration on Thursday approved ​Johnson & Johnson's treatment for a type of ‌blood cancer, ⁠making it ...

Johnson & Johnson (JNJ) units will pay $65M to settle a Tracleer antitrust class action over alleged delays to generic competition. Read more here.

March 4 (Reuters) - Johnson & Johnson has launched a website to sell some of its drugs directly to U.S. patients who either ...

While its "AAA" credit rating, robust free cash flow, and low-debt profile offer a defensive haven in a volatile market, the ...

Johnson & Johnson’s position as a diversified healthcare leader continues to attract attention within equity markets. Through ...

Johnson & Johnson (JNJ) shares jumped 1% on Thursday following reports that the company is eyeing a potential sale of its orthopedics segment. Bloomberg reported, citing people familiar with the ...

March 5 (Reuters) - The U.S. Food and Drug Administration on Thursday approved Johnson & Johnson's treatment for a type of ...

Johnson & Johnson's (JNJ) stock is in focus as the FDA approves a multiple myeloma therapy developed by the company with Halozyme (HALO). Read more here.